Safety of Arthritis Drugs, Day 3. Part 4
This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the three-day forum the 32-member panel had recommended …
140 viewsThis is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the three-day forum the 32-member panel had recommended …
140 viewsAt a joint meeting of the Arthritis and Drug Safety and Risk Management Advisory Committees, experts discussed the safety of arthritis drugs called “COX-2” inhibitors. Dr. Anne Trontell gave…
237 viewsThe Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees continued discussions in their joint meeting on possible safety of risks of “COX-2” inhib…
501 viewsPhysicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drug Arcoxia and for the Food and Drug Administration spoke about a number of issues in…
219 viewsPhysicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drugs Celebrex, Bextra, Parecoxib, and Naproxen spoke as did representatives for the Fo…
340 views